姑息性放射治疗（RT）治疗神经内分泌肿瘤（NEN）的结果很少有报道。我们研究了一组 NEN 患者姑息放疗后的结果。我们假设，分化良好的 NEN 比分化差的 NEN 出现临床反应的可能性更小。使用新西兰网络识别出接受至少一个疗程姑息性 RT 的患者！登记处。排除默克尔细胞癌、肺小细胞癌或无症状患者。分析 90 天内对放疗的临床反应和总体生存率以及临床变量（分割、放疗部位、肿瘤分化和肿瘤原发部位）。该队列由 79 名患者组成，接受了 147 个疗程的姑息性放疗。 100个疗程可测出临床反应，临床反应率为76%。与分化差的 NEN 相比，分化良好的 NEN 的疗程与临床缓解的几率增加 2.02 倍（95% CI 0.67, 6.12；P = 0.21）相关。第一次 RT 后的中位总生存期为 94 天（95% CI 80, 138 天）。高分化 NEN 的总生存率高于低分化 NEN（HR 0.2，95% CI 0.10-0.40，P 值 < 0.001）； 30 天死亡率为 7%。与单次治疗相比，非骨部位以及 >10 次治疗的临床缓解几率显着降低。姑息性放疗是治疗高分化和低分化转移性 NEN 患者症状的适当选择。© 2023作者们。约翰·威利 (John Wiley) 出版的《医学影像和放射肿瘤学杂志》

The outcomes of palliative radiation therapy (RT) for neuroendocrine neoplasms (NEN) are seldom reported. We investigated outcomes following palliative radiotherapy in a cohort of patients with NENs. We hypothesised that well-differentiated NEN will be less likely to have a clinical response than poorly differentiated NEN.Patients who received at least one course of palliative RT were identified using the New Zealand NETwork! Registry. Patients with Merkel cell carcinoma, pulmonary small cell carcinoma or asymptomatic patients were excluded. Clinical response to RT within 90 days and overall survival were analysed alongside clinical variables (fractionation, RT site, tumour differentiation and tumour primary site).The cohort comprised 79 patients, with 147 courses of palliative RT delivered. Clinical response was measurable for 100 courses, with clinical response rate of 76%. A course delivered to a well-differentiated NEN was associated with 2.02-fold (95% CI 0.67, 6.12; P = 0.21) increase in odds of a clinical response compared to a poorly differentiated NEN. Median overall survival from the first fraction of RT was 94 days (95% CI 80, 138 days). Overall survival was higher in well-differentiated NEN than in poorly differentiated NEN (HR 0.2, 95% CI 0.10-0.40, P-value < 0.001); 30-day mortality was 7%. There were significantly reduced odds of clinical response for non-bone sites, and for courses >10 fractions compared to a single fraction.Palliative RT is an appropriate option for management of symptoms in patients with both well- and poorly differentiated metastatic NEN.© 2023 The Authors. Journal of Medical Imaging and Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Radiologists.